SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001493152-24-009741
Filing Date
2024-03-12
Accepted
2024-03-12 20:00:37
Documents
2
Period of Report
2024-01-01

Document Format Files

Seq Description Document Type Size
1 ownership.html 3  
1 ownership.xml 3 1621
2 ex24.htm EX-24 11630
  Complete submission text file 0001493152-24-009741.txt   14814
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Issuer) CIK: 0001855485 (see all company filings)

IRS No.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address
LaPre David (Reporting) CIK: 0002015307 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40789 | Film No.: 24744149